Background Oesophageal adenocarcinoma represents one of the fastest rising cancers in high-income countries. Barrett's oesophagus is the premalignant precursor of oesophageal adenocarcinoma. However, only a few patients with Barrett's oesophagus develop adenocarcinoma, which complicates clinical management in the absence of valid predictors. Within an international consortium investigating the genetics of Barrett's oesophagus and oesophageal adenocarcinoma, we aimed to identify novel genetic risk variants for the development of Barrett's oesophagus and oesophageal adenocarcinoma.
Introduction
Oesophageal adenocarcinoma is a fatal cancer that ranks eleventh in mortality among all malignant disorders. 1 Although new treatment strategies-eg, neoadjuvant chemoradiotherapy-have improved survival, patients with oesophageal adenocarcinoma still have a poor prognosis. 2 Barrett's oesophagus is the premalignant precursor of oesophageal adenocarcinoma and is characterised by a metaplastic change of the stratifi ed squamous epithelium in the distal oesophagus to a glandular so-called intestinalised epithelium. 3 The main risk factor for Barrett's oesophagus is gastro-oesophageal refl ux, whereby gastric acid chronically damages the epithelium of the distal oesophagus. 3 However, although Barrett's oesophagus has an estimated prevalence of up to 5·6% in the population, 4 only a few patients with this disorder-roughly 0·12% every year-develop oesophageal adenocarcinoma. 5 This low progression rate complicates clinical management of Barrett's oesophagus because no valid predictors for the transition from Barrett's oesophagus to oesophageal adenocarcinoma exist, and thus there are no eff ective surveillance and intervention strategies.
Barrett's oesophagus and oesophageal adenocarcinoma have heritable components with substantial overlap in the set of genes contributing to risk of each condition. 6 However, genetic risk factors contributing specifi cally to Barrett's oesophagus or oesophageal adenocarcinoma alone might also exist. So far, genome-wide association studies have identifi ed four loci within or near MHC, FOXF1, GDF7, and TBX5 associated with the development of Barrett's oesophagus, 7, 8 and four additional loci within or near CRTC1, BARX1, FOXP1, and ALDH1A2 associated with development of both Barrett's oesophagus and oesophageal adenocarcinoma. 8, 9 However, because of small sample sizes analysed so far, these loci account for only a part of the genetic variance of Barrett's oesophagus and oesophageal adeno carcinoma. 6 Furthermore, these loci are insuffi cient to predict the transition from Barrett's oesophagus to oesophageal adenocarcinoma, because no specifi c marker for oesophageal adenocarcinoma has been identifi ed up to now. Therefore, our international consortium aimed to do a meta-analysis of all available datasets from genome-wide association studies for Barrett's oesophagus and
Research in context
Evidence before this study We searched PubMed on Feb 29, 2016 , to identify genetic risk markers for Barrett's oesophagus and oesophageal adenocarcinoma identifi ed through genome-wide association studies. We did not apply any publication date restrictions. The search was restricted to papers published in the English language. Search terms were: ("esophageal" OR "oesophageal" OR "esophagus" OR "oesophagus") AND ("Barrett's" OR "adenocarcinoma") AND ("genome wide association study" OR "GWAS"). Three genome-wide association studies have been published to date and have led to the identifi cation of eight genetic risk loci contributing to both Barrett's oesophagus and oesophageal adenocarcinoma. These encouraging fi ndings, however, account for only a part of the genetic risk for Barrett's oesophagus and oesophageal adenocarcinoma. In particular, no variants have been identifi ed so far that contribute solely to development of oesophageal adenocarcinoma and, thereby, might serve as markers for more eff ective surveillance and intervention strategies for Barrett's oesophagus.
Added value of this study
Within an international consortium, we did a meta-analysis of four datasets available to date from genome-wide association studies, totalling more than 27 000 individuals. We identifi ed nine new risk loci for Barrett's oesophagus or oesophageal adenocarcinoma, or both, which represents a doubling of the number of known risk loci. The most strongly associated new risk variant is located within CFTR, mutations of which lead to cystic fi brosis. Patients with cystic fi brosis show highly increased incidence of gastro-oesophageal refl ux, and this refl ux represents the main risk factor for Barrett's oesophagus and oesophageal adenocarcinoma. Therefore, our data suggest that cystic fi brosis, Barrett's oesophagus, and oesophageal adenocarcinoma might have a common pathophysiological feature of gastro-oesophageal refl ux, with CFTR playing an important part in this process. We also identifi ed a risk variant near HTR3C/ABCC5 that was associated solely with development of oesophageal adenocarcinoma. This variant might constitute a novel marker for the prediction of transition from Barrett's oesophagus to oesophageal adenocarcinoma.
Implications of all the available evidence
Identifi cation of novel risk loci and cellular pathways provides further insights into the causes of Barrett's oesophagus and oesophageal adenocarcinoma and impetus for further functional studies. The marker specifi c to oesophageal adenocarcinoma should help to identify patients at higher risk for the transition from Barrett's oesophagus to oesophageal adenocarcinoma. Together, this information should lead to better molecular treatments and individualised prevention and intervention strategies for clinical management of Barrett's oesophagus and oesophageal adenocarcinoma.
oesophageal adenocarcinoma to identify additional genetic variants associated with risk for both disorders. Furthermore, we aimed to identify genetic variants that contribute specifi cally to risk for oesophageal adenocarcinoma and, thereby, might serve as markers for individualised surveillance and intervention strategies for Barrett's oesophagus. To our knowledge, our study is the fi rst in which datasets from genome-wide association studies have been analysed using bioinformatics approaches to gain further information about the underlying genes and cellular pathways associated with Barrett's oesophagus and oesophageal adenocarcinoma.
Methods

Study design and participants
We obtained genome-wide genotype data for patients with Barrett's oesophagus, individuals with oesophageal adenocarcinoma, and representative controls from four genome-wide association studies in Europe, North America, and Australia: 7-9 the Barrett's and Esophageal Adenocarcinoma Consortium (BEACON) study; and studies from Bonn, Cambridge, and Oxford (appendix pp 5-6, 11). Data from the Bonn study are unpublished; the Oxford study did not contribute data for patients with oesophageal adenocarcinoma. All participants were of European ancestry, and DNA samples extracted from blood or saliva were genotyped on high-density single nucleotide polymorphism (SNP) arrays (Illumina, San Diego, CA, USA).
Patients with Barrett's oesophagus were identifi ed by histopathological diagnosis of intestinal metaplasia, and individuals with oesophageal adenocarcinoma had a histopathological diagnosis of adenocarcinoma. We excluded all other patients. Informed consent was obtained in the four studies from all participants and ethics approval was obtained from the ethics boards of every participating institution.
Procedures
We did a quality control assessment of genotyped markers, genotyped individuals, and the imputation, using the same protocol at all participating sites. We used PLINK version 1.90 10 for quality control. We removed all individuals with more than 3% of missing genotypes; SNPs with a successful genotyping rate of less than 97%; SNPs with a minor allele frequency less than 0·01; SNPs with a p value of less than 0·0001 in controls and less than 5 × 10 − ¹⁰ in patients for Hardy-Weinberg equilibrium; and SNPs with a signifi cant (p<0·001) diff erence in missingness between cases and controls. Based on identity by descent calculated from autosomal markers, we removed one of each pair of individuals with high levels of relatedness (p-hat>0·2) and a higher proportion of missing genotypes. We also removed participants who lay beyond six SDs from the mean of the fi rst two genotypic principal components of the 1000 Genomes European descent population.
11
For the imputation, we used SHAPEIT version 2.12 12 for phasing of the genotyped SNPs and IMPUTE2 version 2.3.1 13, 14 for imputation of missing SNPs, using the 1000 Genomes Phase 1 haplotypes (June, 2014 release) as a reference panel. 15 We did the imputation in 5 Mb sections. We set a 250 kb buff er fl anking the imputation sections and an eff ective size of the sampled population of 20 000, as recommended for IMPUTE2 version 2.3.1.
13,14
Statistical analysis
We did association testing for Barrett's oesophagus and oesophageal adenocarcinoma as separate disorders. We then repeated the analysis after combining the two groups of patients into a single group. We assessed associations in SNPTEST version 2.5.2, 16 adjusted for sex and study-specifi c top principal components, under an additive genetic model using dosage scores (based on the probabilities for each of the three possible genotypes of every SNP) obtained from the imputation. Dosage scores account for imputation uncertainty in the association analysis, by contrast with the best-guess approach, whereby the most probable genotype of every SNP obtained from imputation is regarded as the actual genotype for that SNP. We calculated the genomic infl ation factor lambda (λ) to ensure that the results were not aff ected by model mis-specifi cation. A high infl ation factor might indicate presence of population stratifi cation, unknown familial relationships, undetected sample duplications, technical problems with the data, or application of incorrect statistical methods.
We analysed SNPs that passed the post-imputation quality control assessment in every study (imputation quality score >0·4, minor allele frequency >0·001) and were present in at least three studies of Barrett's oesophagus and two studies of oesophageal adenocarcinoma. An imputation quality score greater than 0·4 ensures that SNPs that were not well imputed were excluded, and a minor allele frequency greater than 0·001 ensures that SNPs that were not common in our study population were excluded from the analysis (appendix pp 5-6). We did the meta-analysis with the fi xed-eff ects inverse variance-weighting approach in METAL version 2011-03-25, 17 with a standard genomewide signifi cant threshold of 5 × 10 -⁸. We investigated the presence of genetic heterogeneity between studies with the I² statistic, and we calculated p values for heterogeneity with Cochran's Q test, as implemented in METAL version 2011-03-25. 17 Presence of genetic heterogeneity indicates that eff ect sizes are not similar between studies, emphasising the possibility of a distribution of true eff ect sizes between studies. Random-eff ects meta-analysis deals with this situation by decomposing the observed variance into its two components, within and between study variance, and uses both components for weighting. We did random-eff ects meta-analysis in PLINK version 1.90 10 for all genome-wide signifi cant SNPs that showed signifi cant genetic heterogeneity (p for heterogeneity <0·05).
We created Q-Q and Manhattan plots for the meta-analysis in R. We used LocusZoom version 1.1 18 to create regional association plots for genome-wide signifi cant results.
To investigate whether independent associations exist in regions of genome-wide signifi cance, we did association analyses conditioned on the strongest associated SNP in every region (1 Mb either side of the top SNPs) with meta-analysis summary statistics and the approach implemented in GCTA version 1.25.2. 19 This approach uses both summary-level statistics from genome-wide association studies and estimated linkage disequilibrium from a reference sample (the imputed BEACON data in this study) to investigate whether single or multiple independent associations exist for every locus.
Because some SNPs could be associated with Barrett's oesophagus and oesophageal adenocarcinoma but not meet the genome-wide signifi cance threshold because of insuffi cient statistical power (ie, SNPs with small eff ect sizes cannot be detected in our current sample size using stringent criteria for signifi cance), we used a new approach 20 in which functional annotation information from genome-wide signifi cant loci is used to reweight the results. Incorporating functional annotation information to reweight data from genomewide association studies could result in identifi cation of new risk loci that otherwise might not reach the genome-wide signifi cance threshold in standard genome-wide association studies. This approach, which is implemented in fgwas version 1.0, 20 is capable of identifying additional high-confi dence risk loci, resulting in a roughly 5% increase in the number of identifi ed loci when tested on previously published data from genome-wide association studies. 20 We looked at enrichment of 450 genomic annotations as implemented in fgwas version 1.0 20 (default settings: 5000 SNPs per window). We derived the best annotations from genome-wide signifi cant loci in the Barrett's oesophagus and oesophageal adenocarcinoma combined analysis. We fi rst considered annotations separately to see if they were individually signifi cant. Some annotations were correlated and, hence, we built a model by adding terms sequentially in decreasing order of signifi cance until no more annotations signifi cantly (p<0·05) improved the log-likelihood of the model. We then applied the cross-validation approach implemented in fgwas version 1.0 to ensure no over-fi tting in the fi nal model. We used this fi nal Bayesian model to derive a prior distribution for the remainder of the genome. We calculated the posterior probability of association based on the derived prior distribution. A posterior probability greater than 0·9 in this approach performed similarly to the genome-wide signifi cance threshold in genome-wide association studies (p<5 × 10 -⁸) based on the analysis 20 of previously published genome-wide association studies. 20 We did gene-based association tests with the approach implemented in VEGAS version 2, 21 a simulation-based approach that combines the test statistics for single variants within gene boundaries while accounting for linkage disequilibrium between markers. We set the Bonferroni-corrected threshold for gene-wide signifi cance to a p value of less than 2·8 × 10 − ⁶ (considering 17 787 autosomal genes used in VEGAS version 2).
We analysed pathways and tissue enrichment with methods implemented in DEPICT version 1.1. 22 The preference is to use genome-wide signifi cant SNPs as long as at least ten independent loci are available. However, because of the polygenic basis of complex traits, restricting the pathways analysis to only genomewide signifi cant SNPs might result in some informative data being missed. This omission is because many SNPs that do not meet the genome-wide signifi cance threshold might still be associated with either Barrett's oesophagus or oesophageal adenocarcinoma (or both), but might not be detected because of insuffi cient statistical power. Accordingly, we included loci from the combined Barrett's oesophagus and oesophageal adenocarcinoma meta-analysis that achieved one of three p value thresholds (p<5 × 10 -⁸, p<10 -⁶, and p<10 -⁴) for pathways analysis. We set the Bonferroni-corrected threshold for pathways analysis at a p value of less than 1·15 × 10 -⁶ (considering multiple testing with the three p-value thresholds and assuming all 14 463 pathways used in DEPICT version 1.1 are independent) and a false discovery rate of less than 0·05. Similarly, we set the Bonferronicorrected threshold for tissue-enrichment analysis to a p value of less than 8 × 10 -⁵ (considering multiple testing with the three p-value thresholds and assuming that gene expression in all 209 tissue and cell samples used in DEPICT version 1.1 is independent) and a false discovery rate less than 0·05.
We did bioinformatics analyses as described in the appendix (p 6). We investigated whether published risk loci for gastro-oesophageal refl ux-predisposing traits (eg, body-mass index [BMI] and obesity), which have shown genome-wide signifi cant associations, 23 represent risk loci for Barrett's oesophagus and oesophageal adeno carcinoma. We also estimated the peak SNPs identifi ed in this study in the genome-wide association analysis for BMI undertaken by the Genetic Investigation of ANthropometric Traits (GIANT) consortium. 24 Additional details of methods used for functional annotation enrichment analysis, gene-based analysis, and tissue enrichment analysis are in the appendix (p 7).
Role of the funding source
The funders had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all data in the study, except personal identifying information, and had fi nal responsibility for the decision to submit for publication.
Results
6167 people with Barrett's oesophagus, 4112 individuals with oesophageal adenocarcinoma, and 17 159 representative controls from four genome-wide association studies in Europe, North America, and Australia were included in the meta-analysis. In total, 11 942 825 SNPs for Barrett's oesophagus, 13 074 274 for oesophageal adenocarcinoma, and 11 951 684 for both Barrett's oesophagus and oesophageal adenocarcinoma were used for the meta-analysis of genome-wide association studies. Q-Q and Manhattan plots from the separate Barrett's oesophagus and oesophageal adenocarcinoma meta-analyses, and from the combined Barrett's oesophagus and oesophageal adenocarcinoma metaanalysis, are shown in the appendix (pp 8-9). The scaled genomic infl ation factor lambda (λ) was 1·043 for the Barrett's oesophagus meta-analysis, 1·005 for the oesophageal adenocarcinoma meta-analysis, and 1·049 for the combined Barrett's oesophagus and oesophageal adenocarcinoma meta-analysis.
Five genome-wide signifi cant associated loci (p<5 × 10 -⁸) were identifi ed for Barrett's oesophagus alone, of which three were not previously reported (appendix p 11). Moreover, fi ve genome-wide signifi cant associated loci (p<5 × 10 -⁸) for oesophageal adeno carcinoma alone were identifi ed, of which four were previously unreported (appendix p 12). The combined meta-analysis for Barrett's oesophagus and oesophageal adenocarcinoma identifi ed 14 genome-wide signifi cant associated loci (p<5 × 10 -⁸), of which seven were previously unreported (table) . Of note, all seven new genome-wide signifi cant loci from the separate Barrett's oesophagus and oesophageal adenocarcinoma meta-analyses were also identifi ed in the combined meta-analysis except for one locus on chromosome 3q27 near HTR3C and ABCC5 (rs9823696) that was only recorded in the oesophageal adenocarcinoma meta-analysis and, therefore, was specifi c for this disorder (risk for oesophageal adenocarcinoma: odds ratio [OR] 1·17, 95% CI 1·11-1·24; p=1·64 × 10 -⁸; risk for Barrett's oesophagus: 1·02, 0·97-1·06; p=0·45). By contrast, all risk loci identifi ed for Barrett's oesophagus were also associated with oesophageal adenocarcinoma (at least p<0·02; appendix p 13).
Regional association results for all novel Barrett's oesophagus and oesophageal adenocarcinoma loci are shown in fi gure 1. The most strongly associated SNPs were rs17451754 on chromosome 7q31 within CFTR (p=4·77 × 10 adenocarcinoma and in Barrett's oesophagus. Although we did not identify any secondary peaks (ie, associations of SNPs with oesophageal adenocarcinoma and Barrett's oesophagus that were independent of the top hits) at genome-wide signifi cance in the conditional association analysis of the combined meta-analysis, two loci (rs34817486 near FOXF1-AS1 [also known as FENDRR] and FOXF1, and rs62331139 near LPCAT1 and SLC6A3) showed some evidence of secondary peaks (p<10 -⁵; appendix p 10).
Of the nine newly identifi ed risk loci, only SNPs within or near TPPP and CEP72 showed signifi cant (p<0·05) heterogeneity for the magnitudes of association of SNPs between studies in the fi xed-eff ects meta-analysis (heterogeneity I²=64·5 and p=0·0375 for rs9918259, the most signifi cantly associated SNP at this locus; table). All studies in this meta-analysis showed the same direction of eff ect for risk alleles at this locus. However, the magnitude of association was larger in the Bonn study compared with the other studies-ie, the Bonn study OR was 1·43 (95% CI 1·25-1·64) for the risk allele of rs9918259, whereas it was 1·18 (1·08-1·29) in the BEACON study, 1·11 (0·98-2·49) in the Cambridge study, and 1·12 (0·99-1·28) in the Oxford study. Under a random-eff ects model, the SNP rs9918259 was less signifi cantly associated with Barrett's oesophagus and oesophageal adenocarcinoma in the combined meta-analysis (p=4·7 × 10 -⁴) than with the fi xed eff ects meta-analysis (p=3·2 × 10 -⁹). Consistent with p values for heterogeneity for the other risk loci (table), the magnitude and direction of eff ect were consistent between all studies for the remaining risk loci. Thus, we did not do a random-eff ects meta-analysis for these loci.
All previously reported genome-wide signifi cant loci [7] [8] [9] -including GDF7, ALDH1A2, TBX5, CRTC1, FOXP1, FOXF1, and the MHC region (table)-were also associated with both Barrett's oesophagus and oesophageal adenocarcinoma at the genome-wide signifi cance threshold. Only the BARX1 locus 9 did not meet the genome-wide signifi cance threshold, but it still showed strong association with Barrett's oesophagus and oesophageal adenocarcinoma in the combined meta-analysis (p=6·2 × 10 -⁷ for rs11789015). Apart from the risk loci identifi ed in the single variant analysis, we did not identify other loci reaching gene-based genome-wide signifi cance (p<2·8 × 10 -⁶) after correction for genomic infl ation in the gene-based association analysis (appendix p 7).
In the pathway analyses, no pathways were signifi cantly associated with Barrett's oesophagus and oesophageal adenocarcinoma at the thresholds p<1·15 × 10 -⁶ and false discovery rate <0·05 using SNPs satisfying p<5 × 10 -⁸ and p<10 -⁶ in the combined meta-analysis. However, for SNPs satisfying p<1 × 10 -⁴ in the combined meta-analysis, four pathways were signifi cantly associated with Barrett's oesophagus and oesophageal adenocarcinoma (appendix p 14): negative regulation of muscle-cell diff erentiation (GO:0051148); mesenchyme development (GO:0060485); BMPR2 PPI subnetwork (ENSG00000204217); and mesenchymal cell diff erentiation (GO:0048762). Separate Barrett's oesophagus and oesophageal adeno carcinoma pathways analyses with these thresholds did not identify any signifi cant pathway. In tissue enrichment analyses, genes within the combined Barrett's oesophagus and oesophageal adenocarcinoma associated regions were highly expressed in the digestive system, as well as in the endocrine system, cardiovascular system, and in smooth muscle (appendix pp 7, 15). None of the published genome-wide signifi cant risk loci for BMI and obesity were associated with Barrett's oesophagus and oesophageal adenocarcinoma in the combined meta-analysis at the genome-wide signifi cance level (data not shown). However, rs2898290 (within LINC00208 and BLK), which is strongly associated with Barrett's oesophagus and oesophageal adenocarcinoma (p=1·2 × 10 -⁸), showed some evidence of association with BMI in the GIANT study 24 (p=0·001058). The nine newly identifi ed Barrett's oesophagus and oesophageal adenocarcinoma risk loci were characterised by analysis of multiple functional annotation databases (appendix pp [16] [17] [18] . Many loci harbour genes expressed in the gastrointestinal tract and that have a role in oncogenesis. Furthermore, some of the identifi ed risk variants-or variants that are highly correlated with them (r²>0·80)-represent expression quantitative trait loci that regulate the expression of genes within the regions. Moreover, several of the implicated risk variants change sequence motifs for protein binding sites and are located within DNAase hypersensitivity regions and within regions with enhancer or promoter motifs.
Discussion
Our meta-analysis identifi ed 16 independent risk loci for development of Barrett's oesophagus, oesophageal adenocarcinoma, or both, at the level of genome-wide signifi cance. Nine loci had not been identifi ed before; all previously reported risk loci were associated with both Barrett's oesophagus and oesophageal adenocarcinoma in our meta-analysis. Thus, our study has more than doubled the number of known risk loci for Barrett's oesophagus and oesophageal adenocarcinoma, which further exemplifi es the scientifi c value of meta-analysis of genome-wide association studies through international collaborations. Moreover, we identifi ed an oesophageal adenocarcinoma-specifi c risk locus that was independent of development of Barrett's oesophagus. The sample size of our meta-analysis was large enough to do a pathway analysis to investigate genetic pathways associated with development of Barrett's oesophagus and oesophageal adenocarcinoma. Our fi ndings indicated that cellular pathways involved in muscle-cell diff erentiation and mesenchyme development and diff erentiation were implicated in causing Barrett's oesophagus and oesophageal adenocarcinoma.
Findings of the functional annotation database analysis of the newly identifi ed Barrett's oesophagus and oesophageal adenocarcinoma risk loci exemplify how data from genome-wide association studies can uncover new causal and clinical aspects of Barrett's oesophagus and oesophageal adenocarcinoma (appendix pp 18-19) . The newly identifi ed risk locus with the strongest association with Barrett's oesophagus and oesophageal adenocarcinoma (p=4·8 × 10 -¹⁰) was rs17451754 on chromosome 7q31. This SNP is located within intron 21 of the CFTR gene and aff ects a region marked by enhancer histone modifi cations in the gastrointestinal tract mucosa and by DNAse hypersensitivity. 25 CFTR encodes an ATP-binding cassette membrane protein that functions as a chloride channel and is mutated in cystic fi brosis, 26 the most common autosomal recessive disorder among people of European ancestry. Mutations in CFTR lead to secretions that are abnormally viscous and altered in their chemical composition, leading to severe dysfunction of the respiratory system and gastrointestinal tract. Up to 81% of patients with cystic fi brosis have gastro-oesophageal refl ux, a major risk factor for Barrett's oesophagus and oesophageal adenocarcinoma, and more than 50% of these individuals are treated with proton-pump inhibitors in high-income countries. 27 According to fi ndings of a 20-year nationwide survey from the USA, 28 incidence of cancer at the gastrooesophageal junction is also increased among patients with cystic fi brosis, with evidence of Barrett's oesophagus in these patients. Although the cause of gastro-oesophageal refl ux seems to diff er between most patients with and without cystic fi brosis, the exact mechanism of refl ux in patients with cystic fi brosis is still not understood fully. Favoured pathophysiological ideas about gastrooesophageal refl ux in patients with cystic fi brosis include lower inspiratory intrathoracic pressure with altered gastro-oesophageal pressure gradients, 29 delayed gastric emptying, 30 and impaired neutralisation of refl ux-acidifi ed oesophageal mucosa because of reduced bicarbonate secretion or hyperacidity of refl uxed gastric contents. 31 However, in view of the phenotypic overlap for gastro-oesophageal refl ux and cystic fi brosis, and for gastro-oesophageal refl ux and both Barrett's oesophagus and oesophageal adeno carcinoma, combined with the identifi cation of CFTR risk variants in patients with Barrett's oesophagus and oesophageal adenocarcinoma, it seems plausible that a common pathophysiological mechanism for gastro-oesophageal refl ux is triggered by CFTR. This idea underlines the importance of CFTR as a true disease gene within this region. Fine mapping of all genetic variation at this locus, and extensive functional studies, are needed to test this hypothesis because other pathomechanisms and risk genes cannot be excluded entirely. Moreover, detailed genotype-phenotype studies of Barrett's oesophagus and oeso phageal adenocarcinoma, and of isolated patients with gastro-oesophageal refl ux stratifi ed for the CFTR risk variant, are needed that take the implicated mechanisms of gastro-oesophageal refl ux in cystic fi brosis into account. This work might yield new insights in the area of Barrett's oesophagus and oesophageal adenocarcinoma research.
To our knowledge, the fi rst risk locus to be identifi ed that is specifi c to oesophageal adenocarcinoma is rs9823696 on chromosome 3q27. This SNP lies 4·9 kb downstream of the HTR3C gene. Highly correlated variants of this marker (r²>0·80) have been identifi ed as regulatory active expression quantitative trait loci that aff ect expression of the ABCC5 gene at this locus. 32 However, these regulatory eff ects were studied in blood cells 32 and, thus, further work needs to be done to fi nd out if these expression quantitative trait loci are also present in tissues relevant to oesophageal adenocarcinoma. However, on the functional level, ABCC5 represents an interesting oesophageal adenocarcinoma candidate gene. The corresponding gene product belongs to the group of ATP-binding cassette membrane proteins that play a part in energy-dependent transport of various endogenous and exo genous substrates and has been implicated in cancer development and progression. 33, 34 Furthermore, as with other oesophageal adenocarcinoma genes implicated by genome-wide association studies (eg, FOXF1 and FOXP1), 7, 9 ABCC5 has a role during embryonal develop ment of the intestine. 35 Apart from the exact functional role of rs9823696, markers that contribute solely to oesophageal adenocarcinoma development could serve as predictors for disease progression in Barrett's oesophagus. Because Barrett's oesophagus is common in the population and only a few patients develop oesophageal adenocarcinoma, specifi c markers for the transition of Barrett's oesophagus to oesophageal adeno carcinoma are needed. The risk locus near HTR3C and ABCC5 alone accounts for only a fraction of the phenotypic variance; the OR is 1·17 between patients with oesophageal adenocarcinoma and controls, and 1·02 between individuals with Barrett's oesophagus and controls. However, identifi cation of further oesophageal adenocarcinoma-specifi c markers with larger samples of patients with Barrett's oesophagus and oesophageal adenocarcinoma, together with incorporation of relevant environmental and clinical data (eg, length of Barrett's oesophagus segments, presence of low-grade dysplasia), and application of modern polygenic score approaches will help to identify patients with Barrett's oesophagus at higher risk for oesophageal adenocarcinoma. Development of such risk-prediction methods would be an important advance in clinical management, because this information could be used for more eff ective and individualised surveillance and intervention strategies. Since genetic data can be used for risk prediction at very early stages (eg, before development of Barrett's oesophagus), risk profi ling approaches should also focus on markers that contribute solely to development of Barrett's oesophagus and are independent of the cause of gastro-oesophageal refl ux.
Pathways analyses showed that cellular processes related to muscle-cell diff erentiation and mesenchyme development and cell diff erentiation are associated with development of Barrett's oesophagus and oesophageal adenocarcinoma. Involvement of the muscle-cell differentiation pathway is especially interesting because this pathway might represent a link to cellular mechanisms in the development of hiatal hernias, which have been associated with gastro-oesophageal refl ux and Barrett's oesophagus. 36, 37 In particular, in the most common type 1 hernia, the muscles of the oesophageal hiatus are absent or reduced to a few atrophic strands. 38 Thus, muscle-cell diff erentiation pathways could have a role in formation of hiatal hernia, which in turn might increase the risk for gastro-oesophageal refl ux and Barrett's oesophagus and oesophageal adenocarcinoma. By contrast, both mesenchyme-related pathways imply that the epithelial-mesenchymal transition plays a part in development of Barrett's oesophagus and oesophageal adenocarcinoma, which is characterised by loss of cell adhesion and increased cell migration and invasion. The epithelial-mesenchymal transition represents an essential step in invasion and metastasis of human cancers, particularly in early oesophageal adenocarcinoma originating from Barrett's oesophagus. 39 However, methods used in pathways analyses can diff er between studies, and results are not necessarily consistent. Thus, although the top pathways in this study are supported by the current pathophysiological ideas about Barrett's oesophagus and oesophageal adenocarcinoma, further pathways analyses and functional studies could confi rm the involvement of these pathways in development of Barrett's oesophagus and oesophageal adenocarcinoma.
The only locus that showed signifi cant heterogeneity between studies was related to SNPs within or near TPPP and CEP72. Here, the magnitude of association was larger in the Bonn study than in the other studies included in our meta-analysis. This fi nding points to a so-called winner's curse eff ect (ie, the phenomenon in which the eff ect size of a newly identifi ed genetic association is overestimated because of the insuffi cient statistical power of the original study) in the Bonn study rather than to systematic diff erences between studies, because heterogeneity was only noted at this locus.
Our study has several limitations. Although we have provided bioinformatics evidence for the functional relevance of our fi ndings, we do not provide in-vitro or in-vivo evidence for the biological function of these fi ndings. Further studies are needed to investigate how the identifi ed risk loci contribute to development of Barrett's oesophagus and oesophageal adenocarcinoma at the molecular and cellular level. Moreover, our study included control individuals who were not screened for the presence of Barrett's oesophagus. Although most controls were probably not aff ected by Barrett's oesophagus, inclusion of individuals screened for the absence of Barrett's oesophagus would have increased our power to detect further risk loci for Barrett's oesophagus and oesophageal adenocarcinoma. Furthermore, we did not include genome-wide data from a suffi ciently high number of patients with isolated gastro-oesophageal refl ux. Such data would have enabled us to identify risk variants that are predictive for the transition from gastro-oesophageal refl ux to Barrett's oesophagus. Finally, the sample size of our study has only power for identifi cation of risk loci with moderate eff ects. Although we have used the largest available sample of genome-wide association study data analysed so far from individuals with Barrett's oesophagus and oesophageal adenocarcinoma, further data from additional patients would have led to identifi cation of more risk loci.
In conclusion, our meta-analysis identifi ed nine new risk loci for Barrett's oesophagus and oesophageal adenocarcinoma and highlighted genes and cellular pathways likely to be implicated in disease development. To our knowledge, we have identifi ed for the fi rst time an oesophageal adenocarcinoma association near the HTR3C and ABCC5 genes that is not observed in Barrett's oesophagus. Although the strength of genomewide association study meta-analyses is identifi cation of disease loci, fi ne-mapping and functional studies of new risk loci are now needed to reveal the disease pathophysiology. This next step-together with identifi cation of additional risk loci using larger sample sizes through international collaborative eff orts-should lead to identifi cation of key molecules that have an important role in development of Barrett's oesophagus and oesophageal adenocarcinoma, which should fi nally pave the way for new molecular targets for development of advanced prevention and intervention strategies. 
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